RxDoctor Payments Data

William Dacus, MD

Family Medicine · Lexington, SCNPI 1336162403

Payments from drug & device makers

$8,895in general payments, 2019–2025

Across 551 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • AbbVie$737
  • Pfizer$650
  • Novo Nordisk$620
  • Lilly USA, LLC$601
  • Abbott$452
  • plus $5K from 53 others

What the payments were for

  • Food & beverage$8,76699%
  • Education$1281%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)63$1,101
AbbVie(2 entities)51$737
Pfizer48$650
Novo Nordisk42$620
Lilly USA, LLC45$601
Abbott24$452
GSK21$340
Astellas Pharma US Inc16$326
Amgen21$323
Novartis16$315
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC19$296
Exact Sciences15$249
Bayer13$220
Boehringer Ingelheim14$218
Sanofi-aventis U.S. LLC11$213
Johnson & Johnson14$195
Takeda Pharmaceuticals U.S.A., Inc.12$154
Amarin Pharma, Inc.9$131
Merck8$125
Stryker3$118
Biohaven Pharmaceutical Holding Company Ltd.6$114
Sumitomo Pharma America, Inc.4$102
Lundbeck LLC3$87
Corcept Therapeutics4$79
Daiichi Sankyo Inc.4$74
Phathom Pharmaceuticals, Inc.5$72
Antares Pharma, Inc.4$62
Arbor Pharmaceuticals, Inc.4$62
Currax Pharmaceuticals LLC3$56
Esperion Therapeutics, Inc.3$50
Otsuka America Pharmaceutical, Inc.2$50
Tris Pharma Inc3$49
Supernus Pharmaceuticals, Inc.3$48
Inari Medical, Inc.2$46
Dynavax Technologies Corporation2$39
Kowa Pharmaceuticals America, Inc.3$36
Neos Therapeutics, LP2$34
Halozyme Inc2$32
Dexcom, Inc.2$31
Optinose US, Inc.2$30
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$30
Hikma Pharmaceuticals USA2$29
Actelion Pharmaceuticals US, Inc.1$28
Genentech USA, Inc.2$27
Ironwood Pharmaceuticals, Inc2$27
Axsome Therapeutics, Inc.1$25
Edwards Lifesciences1$21
Boston Scientific1$19
Acadia Pharmaceuticals Inc1$19
Ironshore Pharmaceuticals Inc.1$18
Tolmar, Inc.1$14
Evofem Biosciences, Inc.1$14
Adlon Therapeutics L.p.1$14
Idorsia Pharmaceuticals US Inc1$13
Acerus Pharmaceuticals Corporation1$13
Corium, LLC1$13
Circassia Inc.1$12
Shire North American Group Inc1$11
E.r. Squibb & Sons, L.L.C.1$11

How this compares

$8,895 in reported general payments places this provider in the 90th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$218,023
Medicare patients
619
Services billed
22,033

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin122$140,821
FarxigaDapagliflozin Propanediol122$124,592
EliquisApixaban104$102,888
OzempicSemaglutide73$87,773
RybelsusSemaglutide38$84,230
TrulicityDulaglutide53$68,153
JanuviaSitagliptin Phosphate42$61,203
EntrestoSacubitril/Valsartan46$47,051
Synjardy XrEmpagliflozin/Metformin Hcl32$34,773
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$33,650
JanumetSitagliptin Phos/Metformin Hcl36$32,055
XareltoRivaroxaban38$29,226
LinzessLinaclotide17$17,558
MounjaroTirzepatide15$17,286
MyrbetriqMirabegron23$16,414

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr$218$175,594154 claims
Novo NordiskOzempic, Rybelsus$620$172,003111 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,101$138,557144 claims
PfizerEliquis, Nurtec Odt$650$113,930115 claims
MerckJanuvia, Janumet, Janumet Xr$125$105,22193 claims
Lilly USA, LLCTrulicity, Mounjaro$601$85,44068 claims
NovartisEntresto$315$47,05146 claims
GSKTrelegy Ellipta, Anoro Ellipta$340$43,34163 claims
Johnson & JohnsonXarelto$195$29,22638 claims
AbbVieLinzess, Synthroid$737$22,64476 claims
Astellas Pharma US IncMyrbetriq$326$16,41423 claims
Sumitomo Pharma America, Inc.Gemtesa$102$8,84015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Lexington

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →